GregoryJamesKatoMD(He/Him)
Hematology • King Of Prussia, PASickle Cell & Other Anemias
Executive Director, Global Product Lead, Hematology Therapeutic Area
Dr. Kato is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
CSL Behring
1020 First Ave
King Of Prussia, PA 19406Phone+1 610-290-7452Fax+1 610-290-0452
Summary
- I am a hematologist with an active translational research interest in sickle cell disease, especially how intravascular hemolysis affects the complications of sickle cell disease. My past research experience includes blood flow physiology studies, clinical trials and proteomic analysis of plasma to unravel new mechanisms contributing to pulmonary hypertension and other complications of sickle cell disease. We have formulated a model to suggest that pulmonary hypertension, stroke, leg ulcers and priapism share features of vasculopathy.
After 29 years of patient care, clinical research and molecular biology laboratory research, I have taken a role in the biotech industry to develop new therapeutics for sickle cell disease and other blood disorders.
Education & Training
Johns Hopkins UniversityFellowship, Pediatric Hematology/Oncology, 1988 - 1991
Children's Hospital Los AngelesResidency, Pediatrics, 1985 - 1988
George Washington University School of Medicine and Health SciencesClass of 1985
Certifications & Licensure
PA State Medical License 2013 - 2022
MD State Medical License 1988 - 2014
DC State Medical License 2003 - 2008
Clinical Trials
- A Multi-Center Study of Riociguat in Patients With Sickle Cell Diseases Start of enrollment: 2017 Apr 11
- Topical Sodium Nitrite in Sickle Cell Disease and Leg Ulcers Start of enrollment: 2018 Apr 06
Publications & Presentations
PubMed
- 326 citationsAn amino-terminal c-myc domain required for neoplastic transformation activates transcription.Gregory J. Kato, John Barrett, Manuel Villa-Garcia, Chi V. Dang
Molecular and Cellular Biology. 1990-11-01 - 178 citationsHospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacityRoberto F. Machado, Robyn J. Barst, Nancy A. Yovetich, Kathryn L. Hassell, Gregory J. Kato
Blood. 2011-07-28 - 462 citationsLactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension, and death in patients with sick...Gregory J. Kato, Vicki R. McGowan, Roberto F. Machado, Jane A. Little, James G. Taylor Vi
Blood. 2005-11-16
Journal Articles
- Clinical Outcomes Associated with Sickle Cell Trait: A Systematic ReviewKathryn L Hassell, Rakhi P Naik, Puneet Sahota, Gregory J Kato, Clinton H Joiner, Annals of Internal Medicine
- Simultaneous Polymerization and Adhesion Under Hypoxia in Sickle Cell DiseaseGregory Kato, MD, Proceedings of the National Academy of Sciences
Abstracts/Posters
- Lactate Dehydrogenase to Carboxyhemoglobin Ratio As a Biomarker of Heme Release to Heme Processing Is Associated with Higher Tricuspid Regurgitant Jet Velocity and Ear...Gregory J Kato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Nrf2 Null Mice Are Deficient in CD169+ Macrophages, Associated with Impaired Erythroid Response and Delayed Recovery from Acute Blood LossGregory J Kato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- A Prospective Phase II, Open-Label, Single-Arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients with Pria...Gregory J Kato, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Authored Content
- Sickle Cell DiseaseApril 2021
- Sickle Cell DiseaseMarch 2018
Grant Support
- Use Of Hydroxyurea &L-Arginine Or Sildenafil In Patients W/Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2009–2011
- Treatment Of PH And SCD With Sildenafil TherapyNational Heart, Lung, And Blood Institute2009–2011
- Therapeutic Application Of Intravascular Nitrite For Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2009–2011
- Systemic Nitrite Infusion And Its Effect On Exercise Physiology And MetabolismNational Heart, Lung, And Blood Institute2009–2011
- Synergy Of Hydroxyurea And Erythropoietin On Fetal Hemoglobin In SCDNational Heart, Lung, And Blood Institute2009–2011
- Pulmonary Hypertension And The Hypoxic Response In SCD (PUSH)National Heart, Lung, And Blood Institute2009–2011
- Prevalence Of PAH In SCD Patients In NigeriaNational Heart, Lung, And Blood Institute2009–2011
- Nitric Oxide For Patients With Sickle Cell Anemia And Pulmonary HypertensionNational Heart, Lung, And Blood Institute2009–2011
- Niacin Therapy To Improve Endothelial Function In SCDNational Heart, Lung, And Blood Institute2009–2011
- Natural History Of Sickle Cell Disease And Other Hemolytic DisordersNational Heart, Lung, And Blood Institute2009–2011
- Multicenter Trial Of NO For Acute Treatment Of Sickle Cell Pain EpisodesNational Heart, Lung, And Blood Institute2009–2011
- Cardiopulmonary Function Assessment And NO Based Therapies For SCD PTS With PAHNational Heart, Lung, And Blood Institute2009–2011
- Blood Studies Of Endothelial Function And Systemic InflammationNational Heart, Lung, And Blood Institute2009–2011
- Atorvastatin Therapy To Improve Endothelial Function In Sickle Cell DiseaseNational Heart, Lung, And Blood Institute2009–2011
- Use Of Bosentan In Patients With Symptomatic PH Associated With SCDNational Heart, Lung, And Blood Institute2009–2010
- Nitrite Infusion Studies On Healthy VolunteersNational Heart, Lung, And Blood Institute2009
- Therapeutic Application Of Intravascular Nitrite For SICClinical Center2006
- Atorvastatin Therapy To Improve Endothelial Function InClinical Center2005–2006
- Therapeutic Application Of Intravascular Nitrite For SCDClinical Center2005
- Atorvastatin Endothelial Function In Sickle Cell DiseaseClinical Center2004
- Atorvastatin Therapy And Endothelial Function In SCDClinical Center2003
- Proteolysis Of Leukemia--Related Transcription FactorsNational Cancer Institute1996–2000
- Transcriptional Activation Domain Of C-MYC ProteinNational Cancer Institute1992–1996
- The Transcriptional Activation Domain Of C-MYC ProteinNational Cancer Institute1993
Professional Memberships
- Member
Other Languages
- Spanish
Industry Relationships
- Executive Director, Global Product Lead, CSLGlobal Product Lead for the Hematology Therapeutic Area, currently leading the development of CSL889 Hemopexin and Vamifeport for sickle cell disease and CSL888 Haptoglobin for subarachnoid hemorrhage.Disclosure: Full time employee and equity shareholder2020 - Present
- Consultant, Biogen IdecDisclosure: Consulting fee2014 - 2015
External Links
- CSL Behringhttps://www.cslbehring.com/vita/2021/writing-the-book-on-sickle-cell-disease
- LinkedInhttp://www.linkedin.com/in/gregorykatomd
- ORCIDhttps://orcid.org/0000-0003-4465-3217
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
